Kestra Medical Technologies, Ltd. officer Vaseem Mahboob filed a Form 144 notice on October 29, 2026, disclosing a proposed sale of 4,788 shares of common stock through a broker-assisted cashless exercise of employee stock options.

Key Highlights

  • Proposed sale: Vaseem Mahboob, an officer of Kestra Medical Technologies, Ltd., intends to sell 4,788 shares of common stock with an aggregate market value of $146,502.73.
  • Acquisition method: The shares were acquired on October 29, 2026, through the exercise of employee stock options via a broker-assisted cashless exercise.
  • Broker: Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281, is named as the executing broker.
  • Shares outstanding: According to the filing, approximately 59,561,795 shares of common stock were outstanding at the time of the notice.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of November 5, 2025.
  • Prior sales in past 3 months: The filing discloses seven prior sales of common stock by Mahboob between July 30, 2026, and October 28, 2026, ranging from 3,980 to 39,903 shares per transaction.

Officer Mahboob Discloses Proposed Stock Sale Under Rule 144 at Kestra Medical Technologies

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission on October 29, 2026, Vaseem Mahboob, identified as an officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), intends to sell 4,788 shares of the company's common stock. Kestra Medical Technologies, headquartered at 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington, is a medical technology company. The proposed sale carries an aggregate market value of $146,502.73, and the approximate date of sale is listed as October 29, 2026.

The filing states that the shares to be sold were acquired on October 29, 2026, through the exercise of employee stock options from Kestra Medical Technologies, Ltd., with payment described as a broker-assisted cashless exercise. The notice was filed pursuant to Rule 144 under the Securities Act of 1933, and Mahboob indicated reliance on a Rule 10b5-1 trading plan adopted on November 5, 2025.

The filing also discloses seven separate sales of Kestra Medical Technologies common stock by Mahboob in the three months preceding the notice. Those transactions, dated between July 30, 2026, and October 28, 2026, involved share amounts of 3,980, 8,817, 5,391, 6,995, 26,287, 34,809, and 39,903 shares, with gross proceeds per transaction reported as $90,560.62, $199,344.62, $128,312.27, $172,634.70, $680,383.99, $1,045,784.87, and $1,216,393.08, respectively, according to the filing.

What Was Disclosed

Kestra Medical Technologies officer Vaseem Mahboob filed a Form 144 notice on October 29, 2026, proposing to sell 4,788 shares of common stock valued at $146,502.73, acquired through a cashless employee stock option exercise, with seven prior sales also disclosed.